Cover storyFDA’s Proposed DTC Rule Could End TV Drug Ads
FDA’s Proposed DTC Rule would remove the adequate provision option for broadcast drug ads, requiring full risk information in every spot. See what pharma leaders can do now.
Cover storyFDA’s Proposed DTC Rule would remove the adequate provision option for broadcast drug ads, requiring full risk information in every spot. See what pharma leaders can do now.

IGI's five-mechanism solid tumor IND filing sets a new benchmark for CMC complexity in first-in-class biologics entering FDA review.

Biocon secures EMA marketing authorisation for a pertuzumab biosimilar covering HER2-positive breast cancer across multiple disease stages in the EU.

Pfizer's $2.63B CAR-T licensing deal with Starna Therapeutics raises immediate questions for cell therapy CDMOs on GMP readiness and manufacturing capacity.

Evotec and BMS secure a second FDA IND acceptance for a CELMoD degrader, with Phase 1 entry targeted for 2027.
Latest edition
SPONSORED
SPONSORED
SPONSORED
Nov 23
Nov 28
Dec 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.

